Neuroscience
From the NIH:
Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease
09 December 2010
Read the full press release
- Fda: Approval Of Alzheimer's Neuroimaging Diagnostic Drug, Vizamyl (flutemetamol F 18 Injection)
From the FDA on the 25th of October, quoting the press release: FDA approves second brain imaging drug to help evaluate patients for Alzheimer’s disease, dementia The U.S. Food and Drug Administration today approved Vizamyl (flutemetamol F 18 injection),...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...
- Alzheimer's Disease: Targeting The Blood-brain Barrier
A news release from the NIH: Targeting the Blood-Brain Barrier May Delay Progression of Alzheimer's Disease 12 April 2010Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported...
- Alzheimer's Disease: A-beta And Immune System
Old Enemy Might Help to Prevent Alzheimer’s By GINA KOLATA The New York Times Published: March 8, 2010 "Harvard researchers are taking a new look at beta amyloid, which was thought to be a chief villain in Alzheimer’s whose function was that of a...
- Fibril Structure And Alzheimer Disease
From a Salk Institute for Biological Studies press release:Released: Fri 11-Nov-2005, 08:55 ET Embargo expired: Mon 14-Nov-2005, 17:00 ET 3-D Structure of Alzheimer's Disease Filament Shows How It Zips Up Peptides Newswise — Researchers...
Neuroscience
Alzheimer's: Impaired beta-Amyloid Clearance
From the NIH:
Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease
09 December 2010
In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers funded by the National Institutes of Health have found that in the most common, late-onset form of Alzheimer’s disease, beta-amyloid is produced in the brain at a normal rate but is not cleared, or removed from the brain, efficiently. In addition to improving the understanding of what pathways are most important in development of Alzheimer's pathology, these findings may one day lead to improved biomarker measures for early diagnosis as well as a new approach to treating this devastating disorder.
Many believe that accumulation of abnormal levels of beta-amyloid in the brain initiates a cascade of events leading to the death of brain cells and ultimately to dementia. In the rare, early-onset forms of Alzheimer's that are linked to genetic mutations there is a marked increase in beta-amyloid production. In the more common, late-onset form of Alzheimer's, the mechanisms leading to increased beta-amyloid levels are not well understood.
The study, published in Science, was led by senior author Randall Bateman, M.D., an assistant professor of neurology at Washington University in St. Louis. Dr. Bateman and his colleagues previously reported an innovative procedure to measure beta-amyloid levels over time in cerebrospinal fluid (CSF) — the fluid that bathes the brain. In the new study, the researchers used that procedure to measure beta-amyloid production and clearance rates in study volunteers with Alzheimer’s disease and in age-matched volunteers free of the disease.
"These findings may help point us toward better diagnostic tests and effective therapies. The next question is what is causing the decreased clearance rate," said Dr. Bateman.
Read the full press release
- Fda: Approval Of Alzheimer's Neuroimaging Diagnostic Drug, Vizamyl (flutemetamol F 18 Injection)
From the FDA on the 25th of October, quoting the press release: FDA approves second brain imaging drug to help evaluate patients for Alzheimer’s disease, dementia The U.S. Food and Drug Administration today approved Vizamyl (flutemetamol F 18 injection),...
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...
- Alzheimer's Disease: Targeting The Blood-brain Barrier
A news release from the NIH: Targeting the Blood-Brain Barrier May Delay Progression of Alzheimer's Disease 12 April 2010Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported...
- Alzheimer's Disease: A-beta And Immune System
Old Enemy Might Help to Prevent Alzheimer’s By GINA KOLATA The New York Times Published: March 8, 2010 "Harvard researchers are taking a new look at beta amyloid, which was thought to be a chief villain in Alzheimer’s whose function was that of a...
- Fibril Structure And Alzheimer Disease
From a Salk Institute for Biological Studies press release:Released: Fri 11-Nov-2005, 08:55 ET Embargo expired: Mon 14-Nov-2005, 17:00 ET 3-D Structure of Alzheimer's Disease Filament Shows How It Zips Up Peptides Newswise — Researchers...